Graymatters

2 known investors

GrayMatters Health develops Prism, an interventional psychiatry suite that uses fMRI-informed EEG digital biomarkers and self-neuromodulation to help patients regulate brain activity linked to conditions such as PTSD and depression. It is sold to psychiatry clinics to augment standard-of-care therapies.